I-Mab Stock Is Trading Lower After Unveiling Mid-Stage Trial Data Of Plonmarlimab In Hospitalized COVID-19 Patients

  • I-Mab IMAB has announced interim data from its Phase 2/3 study evaluating plonmarlimab (TJM2 or TJ003234) for cytokine release syndrome (CRS) in patients with severe COVID-19. 
  • Plonmarlimab is designed to target human granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that plays a critical role in acute and chronic inflammation. 
  • The interim analysis showed positive preliminary results in mechanical ventilation-free (MVF) patients at baseline (N=91). 
  • Plonmarlimab treatment resulted in a higher MVF rate (83.6% vs. 76.7%), lower mortality rate (4.9% vs. 13.3%), higher recovery rates (68.9% vs. 56.7%) at day 14, and 80.3% vs. 70.0% at day 30, compared to placebo.
  • The GM-CSF antibody also reduced time to recovery and hospitalization duration, as compared to placebo. 
  • The magnitudes of the clinical improvements were comparable to Humanigen Inc's HGEN lenzilumab in a similar patient population.
  • Biomarker results indicated that patients treated with plonmarlimab had reduced plasma levels of pro-inflammatory cytokines and chemokines critically involved in CRS, excluding not interferon-gamma.
  • Plonmarlimab was well tolerated in all patients with no significant safety concerns.
  • Price Action: IMAB shares are down 8.01% at $72.05 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!